Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 03, 2026 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference

Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference
February 26, 2026 06:58 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 24, 2026 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
February 04, 2026 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in Two February Healthcare Conferences

Aclaris Therapeutics to Participate in Two February Healthcare Conferences
January 27, 2026 06:55 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)

Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
January 12, 2026 06:55 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

Aclaris Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with its Novel Bispecific Antibody ATI-052
January 06, 2026 06:59 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052
December 19, 2025 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index
November 25, 2025 08:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 06, 2025 06:59 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update